RESUMO
In our previous study, Atlantic salmon skin gelatin hydrolysed with flavourzyme possessed 42.5% dipeptidyl-peptidase (DPP)-IV inhibitory activity at a concentration of 5 mg mL(-1). The oral administration of the hydrolysate (FSGH) at a single dose of 300 mg per day in streptozotocin (STZ)-induced diabetic rats for 5 weeks was evaluated for its antidiabetic effect. During the 5-week experiment, body weight increased, and the food and water intake was reduced by FSGH in diabetic rats. The daily administration of FSGH for 5 weeks was effective for lowering the blood glucose levels of diabetic rats during an oral glucose tolerance test (OGTT). After the 5-week treatment, plasma DPP-IV activity was inhibited; the plasma activity of glucagon-like peptide-1 (GLP-1), insulin, and the insulin-to-glucagon ratio were increased by FSGH in diabetic rats. The results indicate that FSGH has the function of inhibiting GLP-1 degradation by DPP-IV, resulting in the enhancement of insulin secretion and improvement of glycemic control in STZ-induced diabetic rats.
Assuntos
Diabetes Mellitus Tipo 2/dietoterapia , Suplementos Nutricionais , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Proteínas de Peixes/uso terapêutico , Gelatina/uso terapêutico , Hidrolisados de Proteína/uso terapêutico , Salmo salar , Animais , Colúmbia Britânica , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/metabolismo , Suplementos Nutricionais/economia , Dipeptidil Peptidase 4/sangue , Dipeptidil Peptidase 4/química , Dipeptidil Peptidase 4/metabolismo , Inibidores da Dipeptidil Peptidase IV/economia , Inibidores da Dipeptidil Peptidase IV/isolamento & purificação , Inibidores da Dipeptidil Peptidase IV/metabolismo , Endopeptidases/metabolismo , Proteínas de Peixes/economia , Proteínas de Peixes/isolamento & purificação , Proteínas de Peixes/metabolismo , Indústria de Processamento de Alimentos/economia , Gelatina/economia , Gelatina/isolamento & purificação , Gelatina/metabolismo , Glucagon/antagonistas & inibidores , Glucagon/sangue , Glucagon/metabolismo , Peptídeo 1 Semelhante ao Glucagon/agonistas , Peptídeo 1 Semelhante ao Glucagon/sangue , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Hiperglicemia/prevenção & controle , Resíduos Industriais/análise , Resíduos Industriais/economia , Insulina/agonistas , Insulina/sangue , Insulina/metabolismo , Secreção de Insulina , Masculino , Hidrolisados de Proteína/economia , Hidrolisados de Proteína/isolamento & purificação , Hidrolisados de Proteína/metabolismo , Ratos Sprague-Dawley , Pele/químicaRESUMO
Comparisons of the bone marrow and serum acid phosphatase values obtained by counter-immunelectrophoresis and the Roy biochemical test were made in 72 patients with and in 13 patients without prostatic cancer. The counter-immunoelectophoresis test, when positive at more than 1 international unit per liter, showed only 4.4 per cent falsely positive results. The Roy biochemical test, which used sodium thymolphthalein monophosphate as the substrate, had 65 per cent falsely positive bone marrow acid phosphatase levels. Conflicting reports regarding the value of bone marrow acid phosphatase determinations in patients with prostatic cancer result from the use of non-specific substrates in biochemical methods for measurement and from the trauma incidental to bone marrow aspiration, which releases many non-prostatic acid phosphatase enzymes. The use of immunoassay such as counter-immunoelectrophoresis minimizes this source of error.
Assuntos
Fosfatase Ácida/metabolismo , Medula Óssea/enzimologia , Ensaios Enzimáticos Clínicos , Contraimunoeletroforese , Imunoeletroforese , Neoplasias da Próstata/diagnóstico , Fosfatase Ácida/sangue , Neoplasias Ósseas/diagnóstico , Neoplasias Ósseas/secundário , Reações Falso-Positivas , Humanos , MasculinoRESUMO
Comparisons of the bone marrow and serum acid phosphatase values obtained by counterimmunoelectrophoresis and the Roy biochemical test were made in 72 patients with and in 13 patients without prostatic cancer. The counter-immunoelectrophoresis test, when positive at more than 1 international unit per liter, showed only 4.4% falsely positive results. The Roy biochemical test, which uses sodium thymolphthalein monophosphate as the substrate, had 65% falsely positive bone marrow acid phosphatase levels. Conflicting reports regarding the value of bone marrow acid phosphatase determinations in patients with prostatic cancer result from the use of non-specific substrates in biochemical methods for measurement and from the trauma incidental to bone marrow aspiration, which releases many non-prostatic acid phosphatase enzymes. The use of immunoassay such as counter-immunoelectrophoresis minimizes this source of error.